Jade Biosciences, Inc.
JBIO
$24.71
$0.903.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.14% | -26.42% | -26.84% | 21.66% | 15.81% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -25.00% | 140.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.31% | -21.27% | 114.72% | -59.55% | -43.10% |
| Change in Net Operating Assets | -112.56% | 188.63% | -889.48% | -158.36% | 15.43% |
| Cash from Operations | -81.29% | 28.43% | -52.09% | -9.75% | -7.47% |
| Capital Expenditure | -- | -- | 94.74% | 58.09% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,052.68% | 91.37% | 33.97% | -- | -- |
| Cash from Investing | -1,052.68% | 91.37% | 33.99% | -109,244.12% | -- |
| Total Debt Issued | -- | -- | -1,209.13% | -107.10% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 429,951.11% | -99.99% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 96.61% | -270.28% | 206.25% | -1,856.00% |
| Cash from Financing | 24,442.52% | -100.47% | -- | -100.00% | 27,429.71% |
| Foreign Exchange rate Adjustments | -900.00% | 58.82% | -325.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 256.40% | -187.01% | 122.44% | -199.90% | 978.93% |